BMO Capital Maintains Outperform on Centessa Pharmaceuticals, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
BMO Capital has maintained an 'Outperform' rating on Centessa Pharmaceuticals and raised its price target from $15 to $20, indicating confidence in the company's future performance.
September 09, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital has increased its price target for Centessa Pharmaceuticals from $15 to $20 while maintaining an 'Outperform' rating, suggesting a positive outlook for the company's stock.
The increase in price target from $15 to $20 by BMO Capital, along with the maintained 'Outperform' rating, indicates strong confidence in Centessa Pharmaceuticals' future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100